Major depressive disorder (MDD) is characterized by persistent depressed mood, loss of interest or pleasure in previously enjoyable activities, recurrent thoughts of death, and physical and cognitive symptoms. People with MDD can have reduced quality of life owing to the disorder itself as well as related medical comorbidities, social factors, and impaired functional outcomes. MDD is a complex disorder that cannot be fully explained by any one single established biological or environmental pathway. Instead, MDD seems to be caused by a combination of genetic, environmental, psychological and biological factors. Treatment for MDD commonly involves pharmacological therapy with antidepressant medications, psychotherapy or a combination of both. In people with severe and/or treatment-resistant MDD, other biological therapies, such as electroconvulsive therapy, may also be offered. Lancet Psychiatry 3 , 472–480 (2016). Article PubMed PubMed Central Google Scholar Tang, S. et al. Abnormal amygdala resting-state functional connectivity in adults and adolescents with major depressive disorder: a comparative meta-analysis. EBioMedicine 36 , 436–445 (2018). Article PubMed PubMed Central Google Scholar Setiawan, E. et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 72 , 268–275 (2015). Article PubMed PubMed Central Google Scholar Kaiser, R. H., Andrews-Hanna, J. R., Wager, T. D. & Pizzagalli, D. A. Diet and the microbiota–gut–brain axis: sowing the seeds of good mental health. Adv. Nutr. https://doi.org/10.1093/advances/nmaa181 (2021). Article PubMed PubMed Central Google Scholar Green, J. E. et al. Feasibility, acceptability, and safety of faecal microbiota transplantation in the treatment of major depressive disorder: a pilot randomized controlled trial. Can. J. Psychiatry 68 , 315–326 (2023). Article PubMed Google Scholar Liu, R. T., Walsh, R. F. & Sheehan, A. E. Prebiotics and probiotics for depression and anxiety: a systematic review and meta-analysis of controlled clinical trials. Neurosci. Biobehav. Rev. 102 , 13–23 (2019). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Focus 16 , 420–429 (2018). This systematic review and meta-analysis compares several antidepressant medications across efficacy, acceptability and tolerability outcomes. Article PubMed PubMed Central Google Scholar Undurraga, J. & Baldessarini, R. J. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 37 , 851–864 (2012). Article CAS PubMed Google Scholar Correll, C. U. et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J. Psychiatr. Res. 96 , 100–107 (2018). Article PubMed Google Scholar Han, C. et al. A pharmacogenomic-based antidepressant treatment for patients with major depressive disorder: results from an 8-week, randomized, single-blinded clinical trial. Clin. Psychopharmacol. Neurosci. 16 , 469 (2018). Article CAS PubMed PubMed Central Google Scholar Oslin, D. W. et al. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME Care randomized clinical trial. J. Am. Med. Assoc. 328 , 151–161 (2022). Article CAS Google Scholar Iosifescu, D. V. Pharmacogenomic testing for next-step antidepressant selection: still a work in progress. J. Am. Med. Assoc. 328 , 146–148 (2022). Article Google Scholar Moraczewski, J. & Aedma, K. K. Tricyclic Antidepressants. StatPearls [online] https://www.ncbi.nlm.nih.gov/books/NBK557791/ (updated 21 November 2022). Kuhn, M., Letunic, I., Jensen, L. J. & Bork, P. The SIDER database of drugs and side effects. Nucleic Acids Res. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychological Med. 41 , 1165–1174 (2011). Article CAS Google Scholar A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int. J. Neuropsychopharmacol. 21 , 97–107 (2018). Article PubMed Google Scholar Plana-Ripoll, O. et al. A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. Lancet 394 , 1827–1835 (2019). Article PubMed Google Scholar Ormel, J. et al. Disability and treatment of specific mental and physical disorders across the world. Br. J. Psychiatry 192 , 368–375 (2008). This publication provides a review of pharmacotherapy interventions currently being trialled and a detailed review of clinical trial considerations relevant to depression research. Article PubMed PubMed Central Google Scholar Marwaha, S. et al. Novel and emerging treatments for major depression. Lancet 401 , 141–153 (2023). Article CAS PubMed Google Scholar Gordon, J. L. et al. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiatry 75 , 149–157 (2018). Article PubMed PubMed Central Google Scholar Deligiannidis, K. M. et al. Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial. JAMA Psychiatry 78 , 951–959 (2021). Article PubMed Google Scholar Sepanjnia, K., Modabbernia, A., Ashrafi, M., Modabbernia, M. J. & Akhondzadeh, S. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology 37 , 2093–2100 (2012). Article CAS PubMed PubMed Central Google Scholar Sarris, J. et al.